CoChat
Sign Up
Cited by 136Monoclonal and Polyclonal Antibodies ResearchSubstance Abuse Treatment and OutcomesImmunotoxicology and immune responses

The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.

Immunotherapy for the treatment of drug abuse

Kosten, Thomas, Owens, S. Michael·2005·Pharmacology & Therapeutics
DOI 10.1016/j.pharmthera.2005.06.009
Open this paper in CoChat — free account

Abstract

Antibody therapy (as either active or passive immunization) is designed primarily to prevent drugs of abuse from entering the central nervous system (CNS). Antidrug antibodies reduce rush, euphoria, and drug distribution to the brain at doses that exceed the apparent binding capacity of the antibody. This is accomplished through a pharmacokinetic antagonism, which reduces the amount of drug in the brain, the rate of clearance across the blood-brain barrier, and the volume of drug distribution. Because the antibodies remain primarily in the circulatory system, they have no apparent central nervous system side effects. Active immunization with drug-protein conjugate vaccines has been tested for cocaine, heroin, methamphetamine, and nicotine in animal, with 1 cocaine and 3 nicotine vaccines in Phase 2 human trials. Passive immunization with high affinity monoclonal antibodies has been tested for cocaine, methamphetamine, nicotine, and phencyclidine (PCP) in preclinical animal models. Antibodies have 2 immediate clinical applications in drug abuse treatment: to treat drug overdose and to reduce relapse to drug use in addicted patients. The specificity of the therapies, the lack of addiction liability, minimal side effects, and long-lasting protection against drug use offer major therapeutic benefit over conventional small molecule agonists and antagonists. Immunotherapies can also be combined with other antiaddiction medications and enhance behavioral therapies. Current immunotherapies already show efficacy, but improved antigen design and antibody engineering promise highly specific and rapidly developed treatments for both existing and future addictions.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.pharmthera.2005.06.009

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 63 references

Research works printed but not linked: 2

  1. Lacy, M., & Owens, S. M. (in press). Molecular engineering an anti-PCP chimeric (mouse/human) monoclonal antibody for treatment of human drug abuse. Exp Biol.
  2. Turpen, 1997, Production of recombinant proteins in plants: pharmaceutical applications. The Soc. Exper. Biol., Canterbury, UK, J Exp Bot, 48

Cited by

Sorted by citations

See all 136

Related

Metadata

Authors
Kosten, T., & Owens, S. M.
Affiliations
  • Yale University (US)
  • University of Arkansas for Medical Sciences (US)
Corresponding author
Kosten, Thomas
ORCID
Venue
Pharmacology & Therapeutics
Publisher
Elsevier BV
Published
2005-10
Volume
108
Issue
1
Pages
76-85
ISSN
0163-7258 (ISSN-L)
DOI
10.1016/j.pharmthera.2005.06.009
OpenAlex
W2089434413
Cited by
135
References
63
Citations by year
2025: 4 · 2024: 2 · 2023: 5 · 2022: 3 · 2021: 3 · 2020: 5 · 2019: 2 · 2018: 4 · 2017: 6 · 2016: 3 · 2015: 5 · 2014: 10 · 2013: 8 · 2012: 6
FWCI
1.51
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Pharmacology & Therapeutics (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institute on Drug Abuse (K05DA000454, U19DA010946, P50DA012762, P50DA018197, R01DA015477, R01DA011560, R01DA007610, P01DA014361)
  • NIH Clinical Center
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
Keywords
antibody therapy, addiction treatment, active immunization, passive immunization, monoclonal antibodies, cocaine, heroin, methamphetamine, nicotine, phencyclidine, blood-brain barrier, drug overdose treatment, relapse prevention, addiction liability, antibody engineering, antigen design
MeSH terms
Animals, Antibodies, Monoclonal, Humans, Immunotherapy, Vaccines, Substance-Related Disorders

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review